BioNexus Gene Lab (BGLC) Non Operating Interest Expenses (2021 - 2026)

BioNexus Gene Lab has disclosed Non Operating Interest Expenses across 6 years of filings, most recently posting $4055.0 for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses fell 16.89% year-over-year to $4055.0; the TTM figure through Jun 2026 stood at $16894.0 (down 22.48% YoY), while the FY2025 annual figure was $19542.0, down 7.59% from the prior year.
• Non Operating Interest Expenses came in at $4055.0 for Q2 2026 at BioNexus Gene Lab, up from $3085.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $6482.0 in Q3 2025 to a low of -$4762.0 in Q4 2022.
• Average Non Operating Interest Expenses over 5 years is $2755.2, with a median of $4119.0 recorded in 2023.
• The largest YoY upside for Non Operating Interest Expenses was 305.55% in 2023 against a maximum downside of 231.18% in 2023.
• Over 5 years, Non Operating Interest Expenses stood at -$4762.0 in 2022, then jumped by 187.84% to $4183.0 in 2023, then surged by 38.94% to $5812.0 in 2024, then slumped by 43.7% to $3272.0 in 2025, then climbed by 23.93% to $4055.0 in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $4055.0 in Q2 2026, $3085.0 in Q1 2026, and $3272.0 in Q4 2025.